Companies / Health Care
TECH
Bio-Techne
Life Sciences Tools & Services
Life Sciences Tools & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health75
Growth28
Profitability71
Cash generation93
Balance sheet100
Dilution control83
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)4.6%Revenue growth (FY)-0.4%Revenue CAGR (3y)2.2%Gross margin65.8%Operating margin20.7%Net margin15.0%Free cash flow margin21.7%R&D / revenue7.8%Stock comp / revenue3.4%Net debt / operating cash flow-0.22xCurrent ratio4.55Diluted share count change-1.7%
| Fiscal year ending | FY 2022-06 | FY 2023-06 | FY 2024-06 | FY 2025-06 | FY 2026-06 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Gross profit | $756M | $770M | $770M | $790M | $799M |
| Operating income | $297M | $299M | $207M | $102M | $252M |
| Net income | $272M | $285M | $168M | $73M | $182M |
| Operating cash flow | $325M | $254M | $299M | $288M | $292M |
| Capital expenditure | $45M | $38M | $63M | $31M | $29M |
| Free cash flow | $280M | $216M | $236M | $257M | $263M |
| R&D | $87M | $92M | $97M | $99M | $95M |
| Stock-based comp | $42M | $39M | $38M | $41M | $41M |
| Buybacks | $161M | $20M | $80M | $276M | $42M |
| Dividends | $50M | $50M | $50M | $50M | $50M |
| Cash | $173M | $181M | $152M | $162M | $265M |
| Total debt | $243M | $350M | $319M | $346M | $200M |
| Equity | $1.7B | $2.0B | $2.1B | $1.9B | $2.1B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.